Amitava Mitra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amitava Mitra has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alison Elizabeth Smith
Kura Oncology, Inc., San Diego, California
21 shared publications - Francis Burrows
Kura Oncology, Inc., San Diego, California
21 shared publications - Hetika Vora Patel
Kura Oncology, Inc., San Diego, California
21 shared publications - Jovylyn Gatchalian Gasendo
Kura Oncology, Inc., San Diego, California
21 shared publications - Linda Kessler
Kura Oncology, Inc., San Diego, California
21 shared publications - Shivani Malik
Kura Oncology, Inc., San Diego, California
21 shared publications
Latest Publications
- 31 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Advancing Evidence Generation in Small, Diverse, Understudied Population
Many clinically important patient groups remain systematically underrepresented in drug development. Among these are patients with severe or time‐varying organ dysfunction, pregnant and lactating women, children with ultrarare diseases, and people from socioeconomically or geographically underserved communities. Traditional clinical trials frequently exclude such groups. Little direct evidence is generated as a result, leaving benefit–risk and dosing decisions uncertain and trial findings poorly generalizable to the patients who will ultimately receive the drug. No single method closes this gap. This review argues that progress instead comes from integration, combining model‐informed drug development, registries and real‐world data, external and virtual controls, Bayesian borrowing, and patient‐centric trial designs into a coherent totality‐of‐evidence package. These tools are maturing from a role that supplements clinical data toward one that can, in defined settings, partially replace it. The appropriate approach may differ by population. For example, (1) mechanistic modeling and exposure prediction for organ replacement therapy/changing organ function or from the altered maternal–fetal–infant physiology that makes prospective studies impractical; (2) registry‐based external controls and natural history data where patients are too few to randomize; and (3) decentralized, partnership‐driven designs to reach populations that structural barriers would otherwise exclude. Three case studies (dose justification across hepatic and renal impairment, evidence generation in women of childbearing potential with chronic autoimmune disease, and a registry‐anchored ultrarare pediatric program) illustrated these approaches. Mapped to evolving regulatory frameworks, these strategies can deliver population‐appropriate dosing at approval rather than through postmarketing commitments, accelerating equitable access to safe and effective therapies.
- 31 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Advancing Evidence Generation in Small, Diverse, Understudied Population
Many clinically important patient groups remain systematically underrepresented in drug development. Among these are patients with severe or time‐varying organ dysfunction, pregnant and lactating women, children with ultrarare diseases, and people from socioeconomically or geographically underserved communities. Traditional clinical trials frequently exclude such groups. Little direct evidence is generated as a result, leaving benefit–risk and dosing decisions uncertain and trial findings poorly generalizable to the patients who will ultimately receive the drug. No single method closes this gap. This review argues that progress instead comes from integration, combining model‐informed drug development, registries and real‐world data, external and virtual controls, Bayesian borrowing, and patient‐centric trial designs into a coherent totality‐of‐evidence package. These tools are maturing from a role that supplements clinical data toward one that can, in defined settings, partially replace it. The appropriate approach may differ by population. For example, (1) mechanistic modeling and exposure prediction for organ replacement therapy/changing organ function or from the altered maternal–fetal–infant physiology that makes prospective studies impractical; (2) registry‐based external controls and natural history data where patients are too few to randomize; and (3) decentralized, partnership‐driven designs to reach populations that structural barriers would otherwise exclude. Three case studies (dose justification across hepatic and renal impairment, evidence generation in women of childbearing potential with chronic autoimmune disease, and a registry‐anchored ultrarare pediatric program) illustrated these approaches. Mapped to evolving regulatory frameworks, these strategies can deliver population‐appropriate dosing at approval rather than through postmarketing commitments, accelerating equitable access to safe and effective therapies.
- Open Access
- 2 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9)
A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling
Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available in some situations. In the case of the menin inhibitor, ziftomenib, a dedicated DDI study in healthy subjects was infeasible due to the potential for toxicity associated with the mechanism of action, so an alternate approach was used. AML patients are typically immuno‐compromised and hence are at a high risk of fungal infections. For this reason, co‐administration of azole antifungals (moderate and strong CYP3A4 inhibitors) was permitted in Clinical Study KO‐MEN‐001. The PK data obtained in the presence or absence of CYP3A4 inhibitors was used to refine the estimate of ziftomenib fm CYP3A4 to 60%–70%. Once refined, the model was applied to predict the victim DDI liability of ziftomenib in the presence of CYP3A4 inhibitors and inducers. Moderate or weak interaction (2.6‐fold and 1.4‐fold increase in AUC) was predicted with itraconazole and isavuconazole, respectively. Approximately 80% reduction in ziftomenib AUC was predicted with rifampicin. Ziftomenib was predicted to be a weak CYP3A4 inhibitor, causing a 1.9‐fold increase in midazolam exposure. In the absence of data from dedicated DDI clinical trials, these results were used to support regulatory interactions with the US FDA regarding concomitant administration of ziftomenib with other medications such as CYP3A4 modulators. These modeling results ultimately supported a range of DDI language in ziftomenib label.
- 2 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9)
Open AccessA Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling
Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available in some situations. In the case of the menin inhibitor, ziftomenib, a dedicated DDI study in healthy subjects was infeasible due to the potential for toxicity associated with the mechanism of action, so an alternate approach was used. AML patients are typically immuno‐compromised and hence are at a high risk of fungal infections. For this reason, co‐administration of azole antifungals (moderate and strong CYP3A4 inhibitors) was permitted in Clinical Study KO‐MEN‐001. The PK data obtained in the presence or absence of CYP3A4 inhibitors was used to refine the estimate of ziftomenib fm CYP3A4 to 60%–70%. Once refined, the model was applied to predict the victim DDI liability of ziftomenib in the presence of CYP3A4 inhibitors and inducers. Moderate or weak interaction (2.6‐fold and 1.4‐fold increase in AUC) was predicted with itraconazole and isavuconazole, respectively. Approximately 80% reduction in ziftomenib AUC was predicted with rifampicin. Ziftomenib was predicted to be a weak CYP3A4 inhibitor, causing a 1.9‐fold increase in midazolam exposure. In the absence of data from dedicated DDI clinical trials, these results were used to support regulatory interactions with the US FDA regarding concomitant administration of ziftomenib with other medications such as CYP3A4 modulators. These modeling results ultimately supported a range of DDI language in ziftomenib label.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 does not inhibit HUVEC tube formation in vitro.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 does not inhibit HUVEC tube formation in vitro.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 induces cell cycle arrest in RCC tumors.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 induces cell cycle arrest in RCC tumors.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Methods from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 (darlifarnib) synthesis.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 (darlifarnib) synthesis.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Anti-tumor efficacy and tolerability of combined KO-2806 and cabozantinib in RCC xenograft models.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Anti-tumor efficacy and tolerability of combined KO-2806 and cabozantinib in RCC xenograft models.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Antiangiogenic tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor receptor (VEGFR) remain the backbone of therapy in advanced renal cell carcinoma (RCC). However, durability of responses is limited and resistance typically arises. Thus, there is an urgent need for therapeutic agents that enhance responses to TKIs, including in patients who progress on prior TKI therapies. In this study, we show that the farnesyl transferase inhibitor (FTI) KO-2806 inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling in endothelial cells to enhance the antiangiogenic properties of TKIs. This translates to tumor regressions and robust inhibition of tumor neovascularization in preclinical models of RCC exposed to the combination of KO-2806 and anti-VEGFR TKIs. KO-2806 also sensitizes tumors previously progressing on anti-VEGFR TKIs, suggesting potential benefits of KO-2806 as a combination partner across the treatment continuum in RCC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Antiangiogenic tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor receptor (VEGFR) remain the backbone of therapy in advanced renal cell carcinoma (RCC). However, durability of responses is limited and resistance typically arises. Thus, there is an urgent need for therapeutic agents that enhance responses to TKIs, including in patients who progress on prior TKI therapies. In this study, we show that the farnesyl transferase inhibitor (FTI) KO-2806 inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling in endothelial cells to enhance the antiangiogenic properties of TKIs. This translates to tumor regressions and robust inhibition of tumor neovascularization in preclinical models of RCC exposed to the combination of KO-2806 and anti-VEGFR TKIs. KO-2806 also sensitizes tumors previously progressing on anti-VEGFR TKIs, suggesting potential benefits of KO-2806 as a combination partner across the treatment continuum in RCC.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Tolerability of KO-2806 with or without axitinib, cabozantinib, or lenvatinib in Caki1 RCC xenograft tumor model.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Tolerability of KO-2806 with or without axitinib, cabozantinib, or lenvatinib in Caki1 RCC xenograft tumor model.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 is tolerable in combination with anti-VEGFR TKIs in RCC tumors progressing on TKIs.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
KO-2806 is tolerable in combination with anti-VEGFR TKIs in RCC tumors progressing on TKIs.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Western blot quantification of Figure 3.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Western blot quantification of Figure 3.